Research programme: cancer therapeutics - Diaxonhit

Drug Profile

Research programme: cancer therapeutics - Diaxonhit

Alternative Names: EHT-107; EHT-6706

Latest Information Update: 05 Jul 2013

Price : $50

At a glance

  • Originator ExonHit Therapeutics
  • Developer Diaxonhit
  • Class Small molecules
  • Mechanism of Action Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 05 Jul 2013 Preclincal development is ongoing in the USA
  • 19 Dec 2012 ExonHit Therapeutics has merged with InGen Biosciences to form Diaxonhit
  • 21 Dec 2010 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top